Insight

Vivek Subbiah: Great discussion with Arielle Medford on the latest and greatest in Precision Medicine and Liquid Biopsy

Vivek Subbiah/LinkedIn

Nov 10, 2024, 16:27

Vivek Subbiah: Great discussion with Arielle Medford on the latest and greatest in Precision Medicine and Liquid Biopsy

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about a recent paper by Arielle Medford, Breast Oncologist at Mass General Cancer Center, published in Nature Reviews Cancer:

“Great discussion with the rising star and physician-scientist Dr. Arielle Medford of Mass General Cancer Center, Harvard Medical School on the latest and greatest in Precision Medicine and Liquid Biopsy.

Huge congratulations on her recent Nature Reviews Cancer paper on ‘A Standing Platform for Cancer Drug Development Using ctDNA-Based Evidence of Recurrence’.

Authors: Arielle Medford, Ariel Carmeli, Alexandra Ritchie, Nikhil Wagle, Levi Garraway, Eric Lander and Aparna Parikh.

More posts featuring Vivek Subbiah.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.

Arielle Medford, MD, is a breast oncologist at Mass General Cancer Center, Harvard Medical School with a research interest in blood-based biomarkers and genomics in breast cancer. She previously served as Chief Resident at Massachusetts General Hospital and has received honors including the Harvard Medical School Resident Teaching Award and the MGH Humanism in Medicine Award.